Opinion|Videos|June 12, 2024
Treating Patients Referred to Academic Centers for CAR T
Focusing on the transition of patients from community practices to academic centers, the panel discusses the initial evaluation and treatment processes, focusing on bridging therapy for patients awaiting CAR T.
Advertisement
Episodes in this series
- From the academic center's perspective, how do you approach the initial consultation and evaluation process for patients referred for CAR T-cell therapy from community practices?
- Are the processes similar across academic settings?
- How do you coordinate care and maintain communication with the academic center during the CAR-T treatment period?
- What is your approach to bridging therapy for patients awaiting CAR-T? How do you decide on the appropriate bridging regimen?
- How closely do you coordinate with academic centers around bridging therapy considerations and processes?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
3
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5